Search

Evidence-backed clinical questions

1. Does dapagliflozin vs placebo affect OUT:cv-death-or-worsening-hf in Heart Failure with Reduced Ejection Fraction? — 1 studies (4,744 patients, 1 RCTs) provide moderate-certainty evidence for benefit of dapagliflozin for Composite of worsening HF or cardiovascular death in Heart Failure with Reduced Ejection Fraction.
2. Does oral anticoagulation vs placebo improve All-Cause Mortality in Atrial Fibrillation? — 21 studies (1,389,742 patients) provide low-certainty evidence for benefit of oral anticoagulation for All-Cause Mortality in Atrial Fibrillation.
3. Does exenatide vs placebo improve All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent? — 5 studies (44,256 patients) provide low-certainty evidence for benefit of exenatide for All-Cause Mortality in Diabetes Mellitus, Non-Insulin-Dependent.
4. Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in Acute Coronary Syndrome? — 3 studies (41,464 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in Acute Coronary Syndrome.
5. Does dabigatran vs warfarin improve outcomes in HEART-VALVE, MECHANICAL? — 3 studies (0 patients) provide low-certainty evidence for benefit of dabigatran for Ventricular Arrhythmia in HEART-VALVE, MECHANICAL.
6. Does amiodarone vs placebo improve outcomes in Atrial Fibrillation? — 10 studies (49,075 patients) provide low-certainty evidence against benefit of amiodarone for Myocardial Infarction Hospitalization in Atrial Fibrillation.
7. Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity? — 3 studies (324 patients) provide low-certainty evidence against benefit of immune checkpoint inhibitors for Cardiac Index in cancer therapy-related cardiovascular toxicity.